Welcome to our dedicated page for Teleflex news (Ticker: TFX), a resource for investors and traders seeking the latest updates and insights on Teleflex stock.
Teleflex Incorporated (NYSE: TFX) is a leading global provider of specialty medical devices for critical care and surgical procedures. Headquartered in Wayne, Pennsylvania, Teleflex employs approximately 12,000 people worldwide and serves healthcare providers in more than 150 countries.
The company’s diverse product portfolio spans across several key segments: vascular access, interventional, anesthesia, surgical, interventional urology, original-equipment manufacturing, and others. These segments collectively cover a wide range of medical needs, from complex surgical interventions to everyday critical care requirements.
Teleflex’s vascular access segment, contributing 24% to 2023 sales, includes innovative solutions for secure and reliable bloodstream access. The interventional segment, accounting for 17%, focuses on cutting-edge devices for minimally invasive procedures. Anesthesia and surgical segments, with 13% and 14% of sales respectively, offer advanced tools and technologies to improve patient outcomes during surgeries.
The company’s interventional urology segment, noted for its UroLift™ System, addresses benign prostatic hyperplasia (BPH) with minimally invasive solutions that preserve patient quality of life. Original-equipment manufacturing and other segments contribute 11% and 10% of sales respectively, underscoring Teleflex’s broad manufacturing capabilities and diverse product offerings.
Teleflex's geographic exposure is primarily in the United States, which generates 60% of its revenue, with international markets contributing the remainder. The company’s global reach and diverse product lines highlight its significant impact on the healthcare industry worldwide.
In recent years, Teleflex has achieved notable success with a 6.5% constant currency revenue growth in 2023, driven by the expansion of its geographic presence and the launch of innovative new products. The company has strategically acquired Palette Life Sciences AB, enhancing its portfolio and operational efficiencies.
Teleflex remains committed to its mission of providing solutions that improve outcomes and enhance safety for patients and healthcare providers. By leveraging purpose-driven innovation, Teleflex continues to address unmet clinical needs and advance healthcare technologies.
For more information about Teleflex and its comprehensive product offerings, please visit teleflex.com.
Teleflex Incorporated has successfully acquired Standard Bariatrics, Inc. for $170 million, with potential additional payments of up to $130 million based on commercial milestones. This acquisition aims to enhance Teleflex's product offerings in bariatric surgery via advanced powered stapling technology. Notably, while the transaction is not expected to materially impact revenue for 2022 and is estimated to dilute adjusted earnings per share by approximately $0.10, it is projected to generate $30-$35 million in revenue for 2023, with further accretive effects on revenue and earnings thereafter.
Teleflex Incorporated (NYSE: TFX) has launched its new Arrow® Pressure Injectable Midline portfolio in the US and Canada as of September 27, 2022. This portfolio includes the Arrowg+ard Blue Advance® Midline designed to enhance patient safety by reducing confusion in line identification, which can lead to medication errors. With 14 kit configurations and features such as antimicrobial protection and eye-catching labeling, it aims to improve procedural efficiency. The innovation stems from collaboration with vascular access professionals.
Teleflex Incorporated (NYSE: TFX) announced the successful findings from the largest real-world evaluation of the MANTA® Device, presented by Dr. Magnus Settergren at the Transcatheter Cardiovascular Therapeutics (TCT) conference. The study, involving 1,048 subjects, showed a 4.2% major vascular complication rate, consistent with previous studies. The MANTA® Device, with over 100,000 units sold globally, is recognized for its safety, effectiveness, and short learning curve, enhancing its applicability in vascular closure for transcatheter aortic valve implantations.
Teleflex Incorporated (NYSE: TFX) will present at the Morgan Stanley 20th Annual Global Healthcare Conference on September 14, 2022, at 10:00 a.m. ET. The speech will be delivered by Liam Kelly, the Chairman, President, and CEO of Teleflex. A live audio webcast of the presentation will be available on the investor section of the Teleflex website. Teleflex specializes in medical technologies that enhance health and quality of life, focusing on innovations in various fields such as vascular access and anesthesia.
Teleflex (NYSE: TFX) has partnered with FundamentalVR to launch a virtual reality (VR) training platform for its UroLift® 2 System, targeting the treatment of benign prostatic hyperplasia (BPH). The platform allows urologists globally, including in newly approved markets like Japan, to practice procedures remotely with tactile feedback and realistic simulations. The training solution aims to improve clinical education access and standardization. Teleflex's UroLift® System is recognized for its minimally invasive approach and lack of new onset erectile dysfunction, benefiting over 350,000 men worldwide.
Teleflex Incorporates Acquisition
Teleflex (NYSE: TFX) announced on August 22, 2022, a definitive agreement to acquire Standard Bariatrics for $170 million in cash, with potential additional payments of up to $130 million based on commercial milestones. The transaction, expected to close in Q4 2022, aims to enhance Teleflex's presence in the sleeve gastrectomy market. Standard Bariatrics anticipates 2022 revenues of $15 million, with expected contributions of $30-$35 million in 2023. However, the acquisition is projected to dilute adjusted earnings per share by $0.10 in 2022 and $0.10 to $0.15 in 2023.
Teleflex (NYSE: TFX) has secured a contract with Vizient, effective August 1, 2022, for supplying Central Venous Access products. This deal allows Vizient's members, which include over 50% of U.S. acute care providers, to access pre-negotiated pricing on Teleflex's products. Teleflex, a market leader in Central Venous Catheters, aims to enhance patient outcomes and minimize complications. The agreement includes Arrowg+ard Blue Plus® CVCs, which significantly reduce central line-associated infections, showcasing Teleflex's commitment to innovation in vascular access.
Teleflex Incorporated (NYSE: TFX) published its 2021 Global Impact Report, outlining achievements in its Corporate Social Responsibility (CSR) program. The report aligns with the Global Reporting Initiative and Sustainability Accounting Standards Board standards.
Key highlights include commitments to reduce energy, water use, and waste, along with the installation of solar panels generating over 5 GWh of renewable electricity. The report emphasizes diversity, equity, and inclusion efforts and investments in tracking environmental metrics, showcasing the company's dedication to ethical governance, sustainability, and community impact.
Teleflex Incorporated (NYSE: TFX) has declared a quarterly cash dividend of $0.34 per share, payable on September 15, 2022. Shareholders of record as of August 15, 2022 will receive this dividend. The company focuses on medical technologies aimed at enhancing health and quality of life, with a diverse product portfolio across various medical fields. For more information, visit teleflex.com.
Teleflex reported second quarter 2022 revenues of $704.5 million, a 1.3% decline year-over-year, but a 2.3% increase on a constant currency basis. GAAP diluted EPS rose to $2.23, up from $1.76 in the previous year. However, the company reduced its 2022 revenue growth guidance to (0.45% to 0.55%) and GAAP EPS guidance to $8.04 to $8.44. The decline was attributed mainly to challenges in the Interventional Urology segment and foreign currency impacts. Despite this, Teleflex remains focused on long-term growth strategies in its high-growth portfolio.
FAQ
What is the current stock price of Teleflex (TFX)?
What is the market cap of Teleflex (TFX)?
What does Teleflex Incorporated do?
Where is Teleflex Incorporated headquartered?
How many people does Teleflex employ?
What are the main segments of Teleflex's business?
What percentage of Teleflex’s revenue comes from the United States?
What recent acquisitions has Teleflex made?
What is the UroLift™ System?
What was Teleflex's revenue growth in 2023?
How can one access Teleflex's investor conference calls?
What is the mission of Teleflex Incorporated?
